Medicina - Xagena Medicina. Xagena.it fornisce informazioni e aggiornamenti sulle Patologie e sulla Terapia medica. Focus su Nuove Terapie per i Tumori.

Metastatic colorectal cancer: better surgical interventions, new chemotherapeutic and biological agents increase 5-year survival from 8 to 30 percent.

Stable coronary artery disease, FDA approves Aceon to reduce risk of cardiovascular mortality or non-fatal myocardial infarction ... FDA ( Food and Drug ...

The endocannabinoid system was discovered through research into delta 9 –tetrahydrocannabinol ( THC ), the active ingredient in cannabis.

The FDA ( Food and Drug Administration ) approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy. In the trial, ...

BAY 94-9343 has demonstrated potent, targeted anti-cancer activity against mesothelin-expressing tumors in preclinical models. Malignant mesothelioma is a rare ...

Overall survival was 8.7 months, a little less than the Bevacizumab only study. In addition, Bevacizumab was well tolerated. While some serious side effects ...

The primary endpoint of the study was the odds of achieving platelet counts between 50,000 and 400,000 microliters in patients receiving Eltrombopag as compared ...

In addition, they tested a genetically engineered virus to deliver two proteins directly to the brain. The findings are reported in the journal Cancer Research.

Yervoy may work by allowing the body's immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously. Yervoy's ...